Use of D9-methadone for postoperative pain relief
Summary
USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.
What changed
USPTO issued Patent No. US12590054B2 to the Board of Regents, The University of Texas System, covering the therapeutic use of d9-methadone for pain management. The patent claims a compound with improved absorption-distribution-metabolism-excretion (ADME) profile, analgesic efficacy, and safety compared to conventional methadone. Inventors include Tatiana N. Nanovskaya, Jun-Ho La, Mahmoud S. Ahmed, and Jigong Wang.
Pharmaceutical companies and healthcare providers should review this patent for potential licensing implications when developing or using methadone-based pain treatments. Freedom-to-operate analyses should consider this IP if developing similar compounds. The patent term extends 20 years from the December 22, 2022 filing date.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of D9-methadone for postoperative pain relief
Grant US12590054B2 Kind: B2 Mar 31, 2026
Assignee
Board of Regents, The University of Texas System
Inventors
Tatiana N. Nanovskaya, Jun-Ho La, Mahmoud S. Ahmed, Jigong Wang
Abstract
Certain embodiments are directed to the use of d9-methadone as an alternative formulation for methadone, the d9-methadone having an improved absorption-distribution-metabolism-excretion profile, analgetic efficacy, and safety for the management of pain following injury such as trauma, disease, and surgery.
CPC Classifications
A61K 31/137 A61K 45/06 A61P 25/04 C07B 59/001 C07C 225/06
Filing Date
2022-12-22
Application No.
18087350
Claims
15
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.